Table 1 Baseline characteristics of the study participants
CPAP group (N = 63) | Usual-care group (N = 68) | P | |
|---|---|---|---|
Age, years | 62.2 ± 7.2 | 61.5 ± 7.4 | 0.563 |
Male, N (%) | 53 (84.1%) | 55 (80.9%) | 0.626 |
Anthropometric measurements | |||
BMI, kg/m2 | 43 (68.3%) | 47 (69.1%) | 0.915 |
Waist circumference, cm | 92.4 ± 8.7 | 92.9 ± 9.8 | 0.754 |
Hip circumference, cm | 98.0 (94.0, 103.0) | 101.0 (97.0, 105.0) | 0.100 |
Neck circumference, cm | 38.6 ± 3.2 | 38.6 ± 3.2 | 0.981 |
Waist-hip ratio | 0.93 ± 0.05 | 0.92 ± 0.05 | 0.171 |
Systolic pressure, mmHg | 120.0 (115.0, 130.0) | 120.0 (110.0, 130.0) | 0.427 |
Diastolic pressure, mmHg | 70.0 (64.0, 80.0) | 70.0 (65.8, 80.0) | 0.745 |
Pulse, beats/min | 63.0 (56.0, 68.0) | 63.0 (59.0, 68.0) | 0.452 |
Sleep monitoring | |||
AHI, per hour | 23.0 (16.0, 35.5) | 24.5 (17.5, 41.8) | 0.547 |
ODI, per hour | 19.5 (15.0, 35.5) | 24.5 (16.0, 37.0) | 0.410 |
Snoring, per hour | 1499.0 (659.3, 2352.3) | 1198.5 (634.0, 2430.8) | 0.734 |
Mean oxygen saturation, % | 94.0 (93.0, 95.0) | 94.0 (93.0, 95.0) | 0.673 |
Nidir oxygen, % | 81.0 (72.0, 83.0) | 78.0 (72.0, 82.0) | 0.381 |
Time with oxygen saturation less than 90%, min | 22.0 (8.8, 60.8) | 24.0 (12.0, 55.5) | 0.569 |
ESS | 7.0 (5.0, 9.0) | 5.0 (4.3, 6.0) | < 0.001 |
Sham CPAP, hours | 5.4 ± 1.3 | 5.5 ± 1.2 | 0.654 |
Comorbidity | |||
Myocardial infarction, N (%) | 21 (33.3%) | 24 (35.3%) | 0.813 |
PTCA, N (%) | 26 (41.3%) | 28 (41.2%) | 0.991 |
CABG, N (%) | 5 (7.9%) | 0 (0.0%) | 0.018 |
Angina, N (%) | 20 (31.7%) | 22 (32.4%) | 0.941 |
Heart failure, N (%) | 1 (1.6%) | 2 (2.9%) | 0.605 |
Hypertension, N (%) | 55 (87.3%) | 59 (86.8%) | 0.927 |
Stroke, N (%) | 27 (42.9%) | 29 (42.6%) | 0.981 |
TIA, N (%) | 5 (7.9%) | 4 (5.9%) | 0.642 |
Diabetes mellitus, N (%) | 20 (31.7%) | 16 (23.5%) | 0.293 |
Medications | |||
Aspirin, N (%) | 39 (61.9%) | 49 (72.1%) | 0.216 |
Clopidogrel, N (%) | 27 (42.9%) | 34 (50.0%) | 0.413 |
Statin, N (%) | 42 (66.7%) | 42 (61.8%) | 0.559 |
Beta-blocker, N (%) | 27 (42.9%) | 33 (48.5%) | 0.515 |
ARB, N (%) | 24 (38.1%) | 25 (36.8%) | 0.875 |
ACE inhibitors, N (%) | 9 (14.3%) | 9 (13.2%) | 0.861 |
CCB, N (%) | 32 (50.8%) | 31 (45.6%) | 0.551 |
Nitrates, N (%) | 2 (3.2%) | 6 (8.8%) | 0.177 |
Insulin, N (%) | 0 (0.0%) | 1 (1.5%) | 0.334 |
Antidiabetic oral medication, N (%) | 12 (19.0%) | 13 (19.1%) | 0.992 |
Chinese medicine, N (%) | 2 (3.2%) | 2 (2.9%) | 0.938 |
Number of medication usage | 4.0 (3.0, 5.0) | 4.0 (3.0, 5.0) | 0.540 |
Death, N (%) | 3 (4.8%) | 5 (7.4%) | 0.536 |
Secondary endpoint, N (%) | 8 (12.7%) | 13 (19.1%) | 0.317 |
Follow-up time, months | 42.0 (32.0, 54.0) | 43.5 (36.0, 54.8) | 0.810 |